HCPCS A4290 is officially defined as "Sacral nerve stimulation test lead, each." HCPCS A4290 is referenced in 14 tracked payer policy changes from Harvard Pilgrim Health Care, Excellus BlueCross BlueShield, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS A4290 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Effective January 1, 2026, Harvard Pilgrim Health Care Commercial plans will deny claims for specific procedure codes unless proper diagnosis codes are also submitted. Claims for procedure codes 64561, 64581, or A4290 require a diagnosis of urinary or fecal incontinence, and ambulatory blood pressure monitoring codes (93784-93790) require elevated blood pressure without hypertension diagnosis.
Excellus BlueCross BlueShield policy 7.01.10, Sacral Nerve Stimulation, has a current effective date of March 16, 2026. The November 20, 2025 off-cycle review clarified the sacral nerve stimulation trial and permanent placement criteria. Sacral nerve stimulation is medically appropriate for individuals 16 and older who meet both the trial stimulation and permanent placement criteria, and it is considered investigational for stress incontinence, urge incontinence due to a neurological condition, other chronic voiding dysfunction, constipation, chronic pelvic pain and bilateral sacral nerve stimulation.
Independence Blue Cross reissued Policy 11.17.04z to add two new CPT codes (0988T and 0989T) as experimental/investigational effective 01/01/2026. These codes are excluded from coverage for all Independence Blue Cross products and are not eligible for reimbursement. The policy also reaffirms existing coverage criteria for sacral nerve stimulation (SNS) and posterior tibial nerve stimulation (PTNS) for incontinence treatment.
Aetna Clinical Policy Bulletin 0679 (last review 10/26/2026) considers high-voltage pulsed electro-galvanic stimulation medically necessary for refractory levator syndrome (chronic anal pain syndrome) when all listed criteria are met: no neurological cause for the pain can be detected, the member has failed prior conservative treatments, and no underlying disease has been revealed by anorectal examination, manometry, radiology, or endoscopy. Biofeedback is medically necessary for refractory levator syndrome when those same criteria are met, while pudendal nerve injection with corticosteroids or other agents, sacral nerve stimulation, and trans-lumbosacral neuromodulation therapy are considered experimental, investigational, or unproven for this indication.
Policy A.7.01.69 states that sacral nerve neuromodulation may be considered medically necessary as a trial for urge incontinence, urgency-frequency syndrome, non-obstructive urinary retention, or overactive bladder when the listed criteria are met, and as a trial for chronic fecal incontinence when its separate criteria are met. Permanent implantation may be considered medically necessary when those criteria are met and a trial stimulation period shows at least 50% improvement in symptoms over at least 48 hours, while chronic constipation, chronic pelvic pain, stress incontinence, and urge incontinence due to a neurologic condition are investigational. The policy was updated on 09/17/2026 to change the device description, renumber the urinary incontinence Criteria A statements, and remove ICD-9 procedure and diagnosis codes from the code reference section.
Aetna considers a trial of percutaneous dorsal column stimulation medically necessary for chronic pain from failed back surgery syndrome with low back pain and significant radicular pain, complex regional pain syndrome types 1 and 2, inoperable chronic ischemic limb pain secondary to peripheral vascular disease, or moderate to severe (5 or more on a 10-point VAS scale) chronic neuropathic pain of certain origins present for 12 or more months, when the listed criteria are met. Permanent implantation follows a trial that gives 50% or more pain relief. Cervical dorsal column stimulation for any indication other than upper extremity CRPS, dorsal column stimulation for many other conditions, and the combined use of dorsal column and dorsal root ganglion stimulation for CRPS are considered experimental, investigational or unproven. Dorsal root ganglion stimulators are covered for moderate to severe chronic intractable pain of the lower limbs in CRPS types I and II when the general spinal cord stimulator criteria are met.
Aetna's Clinical Policy Bulletin 0611 covers fecal incontinence. It considers anorectal manometry, anorectal ultrasonography, rectal sensory testing, biofeedback, bowel training, defecation programs, diet modification and pharmacotherapy medically necessary, and it lists anal sphincter repair, colostomy, the Acticon Neosphincter and sacral nerve stimulation as invasive treatments that need all diagnostic tests and a 3-month trial of two or more traditional treatments first, unless contraindicated. Several other treatments are listed as experimental, investigational or unproven, including anal slings, graciloplasty, injectable bulking agents, magnetic anal sphincter augmentation, posterior tibial nerve stimulation, topical estrogen, topical oxymetazoline, trans-anal radiofrequency therapy (Secca) and vaginal bowel control (Eclipse system).
Aetna Clinical Policy Bulletin 0223 on urinary incontinence, reviewed 2026-07-16, considers multi-channel urodynamic studies medically necessary when a member has both symptoms and physical findings of urinary incontinence or voiding dysfunction and the provider is considering invasive, potentially morbid or irreversible treatment after conservative management has failed. It considers medically necessary the artificial urinary sphincter, FDA-cleared peri-urethral bulking agents, permanent sacral nerve stimulators after temporary trial stimulation, percutaneous tibial nerve stimulation, weighted vaginal cones, pessaries, tension-free and transobturator tape procedures, colposuspension and sub-urethral sling procedures when the stated criteria are met. Bilateral permanent sacral nerve stimulator implantation, the Genityte and FemiLift laser procedures, stem cell therapy and many other listed interventions are considered experimental, investigational or unproven.
Aetna Clinical Policy Bulletin 0194 sets the criteria for spinal cord stimulation. A trial of percutaneous dorsal column stimulation is considered medically necessary for failed back surgery syndrome with low back pain and significant radicular pain, for complex regional pain syndrome types 1 and 2, for inoperable chronic ischemic limb pain secondary to peripheral vascular disease, and as a last resort for moderate to severe (5 or more on a 10-point VAS) chronic neuropathic pain of 12 or more months from the listed origins, when the policy criteria are met.
Aetna covers sacral nerve stimulation for members with chronic fecal incontinence who have had an inadequate response to conservative treatment and have a weak but structurally intact anal sphincter. A temporary percutaneous peripheral nerve electrode is tested first, and a permanent implantable pulse generator is medically necessary only for members who have a 50% or greater improvement in incontinence symptoms from the temporary stimulation over a period of at least 48 hours. Anal sphincter repair, colostomy and the Acticon Neosphincter artificial bowel sphincter are medically necessary for severe fecal incontinence, defined as involuntary loss of solid or liquid stool on a weekly or more frequent basis, after all diagnostic tests and a 3-month trial of 2 or more traditional treatments, unless contraindicated, and after failure of or inability to use medical interventions. Anal slings, graciloplasty, injectable bulking agents, transanal radiofrequency therapy (Secca procedure), posterior tibial nerve stimulation, topical estrogen and several other listed treatments are considered experimental, investigational or unproven.
Aetna considers embolization of gonadal or ovarian veins, with or without the internal iliac veins, medically necessary for pelvic congestion syndrome when the member has had a definitive diagnostic venography, CT or MRI and has failed a trial of appropriate pharmacotherapy such as analgesics or hormonal therapy. Gonadal or ovarian vein embolization for pelvic congestion syndrome is experimental, investigational, or unproven when those criteria are not met. Median sacral vein embolization for pelvic congestion syndrome, ovarian vein transposition, sacral nerve root neuromodulation for chronic pelvic pain, and micronized purified flavonoid fraction for pelvic congestion syndrome are listed as experimental, investigational, or unproven.
Aetna considers continuous epidural analgesia medically necessary for intractable CRPS when the member has had pain for more than 3 months despite conservative therapy, has failed a trial of physical therapy, and has failed a trial of nerve blocks with local anesthetics and steroids. Sympathetic blocks (stellate ganglion and lumbar sympathetic blocks) are medically necessary for diagnosis and treatment when 3 months of conservative treatment, including analgesia and physical therapy, has failed, with up to 3 injections considered medically necessary and repeat blocks beyond the first 3 considered medically necessary only as part of a comprehensive pain management program. Dorsal column stimulators are medically necessary durable medical equipment for CRPS when the member meets all criteria in CPB 0194, Spinal Cord Stimulation, and Aetna considers many other listed approaches experimental, investigational or unproven for CRPS.
A trial of sacral nerve neuromodulation, using percutaneous nerve stimulation or a temporarily implanted lead, may be considered medically necessary for urge incontinence, urgency-frequency syndrome, non-obstructive urinary retention, or overactive bladder when the listed criteria are met. Permanent implantation may be considered medically necessary when those criteria are met and a trial stimulation period demonstrates at least 50% improvement in symptoms over at least 48 hours. For chronic fecal incontinence, a trial may be considered for more than 2 incontinent episodes on average per week for more than 6 months, or more than 12 months after vaginal childbirth, after documented failure of conventional conservative therapy. Sacral nerve neuromodulation is considered investigational for chronic constipation, chronic pelvic pain, stress incontinence, and urge incontinence due to a neurologic condition. The 09/17/2026 update revised device descriptions, re-numbered the Criteria A statements for urinary incontinence, and removed ICD-9 procedure and diagnosis codes from the code reference.
Independence Blue Cross reissued MA11.028l on 01/21/2026 to communicate the company's continuing position on Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for incontinence control. Two new experimental/investigational CPT codes (0988T and 0989T) were added effective 01/01/2026 and are NOT covered. No changes to existing coverage criteria or medically necessary procedures.
Watch A4290
Get one email when a payer policy names A4290, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for A4290
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for A4290 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.